Allogeneic Cell Therapy Market: By Cell Type (Allogeneic CAR-T, NK Cell, Gamma-Delta T Cell, Mesenchymal Stromal Cell, iPSC-Derived); Source (Healthy Donor, Induced Pluripotent Stem Cell, Cord Blood); Indication (Hematologic Malignancies, Solid Tumors, Autoimmune Disease, Regenerative/Graft-versus-Host Disease); Development Stage (Preclinical, Clinical, Approved); End User (Hospitals & Cancer Centers, Biopharma, CDMOs)—Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026–2035
The allogeneic cell therapy market is estimated at USD 800.1 million in 2025 and is projected to reach USD 11,988.3 million by 2035, growing at a CAGR of 31.1% over the forecast period 2026–2035. Read More
We Are Trusted By These Great Companies!
Last Updated: 02-Sep-2026 | Format: | Report ID: AA09261959